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Abstract
Background
In studies including the general population, the presence of non-malignant monoclonal gam-
mopathy (MG) can be causally associated with kidney damage and shorter survival. We
assessed whether the presence of an MG is associated with a higher risk of kidney failure or
death in individuals with chronic kidney disease (CKD).
Methods and findings
Data were used from 3 prospective cohorts of individuals with CKD (not on dialysis or with a
kidney transplant): (1) Renal Impairment in Secondary Care (RIISC, Queen Elizabeth Hos-
pital and Heartlands Hospital, Birmingham, UK, N = 878), (2) Salford Kidney Study (SKS,
Salford Royal Hospital, Salford, UK, N = 861), and (3) Renal Risk in Derby (RRID, Derby,
UK, N = 1,739). Participants were excluded if they had multiple myeloma or any other B cell
lymphoproliferative disorder with end-organ damage. Median age was 71.0 years, 50.6%
were male, median estimated glomerular filtration rate was 42.3 ml/min/1.73 m2, and
median urine albumin-to-creatinine ratio was 3.4 mg/mmol. All non-malignant MG was iden-
tified in the baseline serum of participants of RIISC. Further, light chain MG (LC-MG) was
identified and studied in participants of RIISC, SKS, and RRID. Participants were followed
up for kidney failure (defined as the initiation of dialysis or kidney transplantation) and death.
Associations with the risk of kidney failure were estimated by competing-risks regression
(handling death as a competing risk), and associations with death were estimated by Cox
proportional hazards regression. In total, 102 (11.6%) of the 878 RIISC participants had
an MG. During a median follow-up time of 74.0 months, there were 327 kidney failure
events and 202 deaths. The presence of MG was not associated with risk of kidney failure
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(univariable subhazard ratio [SHR] 0.97 [95% CI 0.68 to 1.38], P = 0.85; multivariable SHR
1.16 [95% CI 0.80 to 1.69], P = 0.43), and although there was a higher risk of death in uni-
variable analysis (hazard ratio [HR] 2.13 [95% CI 1.49 to 3.02], P < 0.001), this was not sig-
nificant in multivariable analysis (HR 1.37 [95% CI 0.93 to 2.00], P = 0.11). Fifty-five (1.6%)
of the 3,478 participants from all 3 studies had LC-MG. During a median follow-up time of
62.5 months, 564 of the 3,478 participants progressed to kidney failure, and 803 died. LC-
MG was not associated with risk of kidney failure (univariable SHR 1.07 [95% CI 0.58 to
1.96], P = 0.82; multivariable SHR 1.42 [95% CI 0.78 to 2.57], P = 0.26). There was a higher
risk of death in those with LC-MG in the univariable model (HR 2.51 [95% CI 1.59 to 3.96],
P < 0.001), but not in the multivariable model (HR 1.49 [95% CI 0.93 to 2.39], P = 0.10). An
important limitation of this work was that only LC-MG, rather than any MG, could be identi-
fied in participants from SKS and RRID.
Conclusions
The prevalence of MG was higher in this CKD cohort than that reported in the general popu-
lation. However, the presence of an MG was not independently associated with a signifi-
cantly higher risk of kidney failure or, unlike in the general population, risk of death.
Author summary
Why was this study done?
• Non-malignant monoclonal gammopathy (MG) is a common pre-malignant condition
that can be associated with kidney damage and a higher risk of death.
• Chronic kidney disease (CKD) is also common, affecting approximately 10% of adults,
and people with CKD may be more likely to have an MG.
• It is unknown whether having an MG is associated with higher risk of kidney failure or
death in people with CKD.
What did the researchers do and find?
• We examined how common an MG is in patients with CKD, and also examined the
associations between MG and kidney failure and death using data from 3 cohort studies
of patients with CKD in the UK.
• An MG was present in 11.6% of patients with CKD.
• Patients with an MG did not have a higher risk of kidney failure or death.
What do these findings mean?
• Our results are consistent with a previous study that suggested that MG is more com-
mon in patients with CKD.
• However, the presence of an MG was not associated with a higher risk of kidney failure
or death.
Non-malignant monoclonal gammopathy in chronic kidney disease
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• Although this is reassuring for patients with CKD and their healthcare providers, we did
not examine whether having an MG is associated with the risk of other adverse
outcomes.
Introduction
Monoclonal gammopathy (MG) is a prevalent condition [1] that can indicate a malignant B
cell disorder such as multiple myeloma, but more often results from a pre-malignant B cell
clone with no demonstrable organ damage (MG of undetermined significance, MGUS) [2,3].
MGUS is common, affecting around 3% of those aged over 50 years [1], and requires monitor-
ing but not targeted therapy. However, a non-malignant MG can, rarely, be causally associated
with kidney damage (MG of renal significance [MGRS]), where specific targeted therapy is
indicated to preserve organ function [4].
Several studies in general populations have shown that the presence of MGUS is associated
with shorter survival [5,6], and the prevalence of MGUS in patients with chronic kidney dis-
ease (CKD) has been reported to be higher than in the general population [7,8]. However, to
the best of our knowledge, there has been only 1 small study examining the prognostic signifi-
cance of MGUS in patients with CKD [7]. The study found that those with MGUS were not at
a significantly higher risk of kidney failure or, unlike in the general population, death [7].
This study was performed to determine the prevalence of non-malignant MG in a CKD
population and to evaluate whether the presence of a non-malignant MG adds to the risk of
adverse outcomes in CKD. We tested the pre-specified hypotheses that the presence of a non-
malignant MG is independently associated with a higher risk of kidney failure and shorter sur-
vival in patients with CKD.
Methods
A prospective analysis plan was written (S1 Protocol). This study is reported as per the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
(S1 STROBE Checklist).
Patients
Patients from 3 prospective UK cohorts of individuals with CKD who had not received kidney
replacement therapy (KRT, i.e., dialysis or kidney transplant) were included: Renal
Impairment in Secondary Care (RIISC; ClinicalTrials.gov: NCT01722383), the Salford Kidney
Study (SKS, previously termed the Chronic Renal Insufficiency Standards Implementation
Study [CRISIS]), and Renal Risk in Derby (RRID; National Institute for Health Research study
ID: 6632).
Each study had research ethics committee (REC) approval (RIISC: West Midlands South
Birmingham REC, ref 10/H1207/6; SKS: North West Greater Manchester South REC; ref 15/
NW/0818; RRID: East Midlands Nottingham 1 REC). All participants in all 3 studies provided
written informed consent, and all studies were conducted in accordance with the Declaration
of Helsinki.
Complete details of these cohorts have been reported elsewhere [9–11], and the inclusion
and exclusion criteria are summarised in Table 1. For this analysis, participants were excluded
Non-malignant monoclonal gammopathy in chronic kidney disease
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at an individual level if they had a malignant MG (multiple myeloma or another malignant B
cell lymphoproliferative disorder).
Definition of MG
Although the majority of included participants with MG will have had MGUS, we have used
the more general term non-malignant MG to reflect the fact that only a minority of partici-
pants had kidney biopsies to exclude MGRS definitively. Two forms of non-malignant MG
were assessed: (1) any non-malignant MG (assessed in the RIISC cohort only), defined as (a) a
monoclonal protein on serum protein electrophoresis (SPEP) confirmed by serum immuno-
fixation or (b) a serum κ/λ free light chain (FLC) ratio < 0.37 or>3.10 with an increased level
of the involved light chain, or (2) light chain MG (LC-MG) (assessed in all 3 cohorts), defined
as a serum κ/λ FLC ratio < 0.37 or >3.10 with an increased level of the involved light chain.
The Freelite assay (Binding Site, Birmingham, UK) was used to measure κ and λ FLC con-
centration in all 3 cohorts. The serum κ/λ FLC ratio reference range of 0.37 to 3.10 has been
recommended in patients with kidney impairment to account for the associated change in
FLC clearance [12,13]. For the RIISC cohort, SPEP and immunofixation were also performed
on baseline serum using standard laboratory procedures.
Study design
Patients were recruited prospectively in all 3 cohorts, and data and biological samples collected
at baseline visits were used for this analysis. Years of recruitment, end of follow-up, and
median follow-up time for each study are given in Table 1. Time-to-event data were collected
for 2 clinical endpoints: (1) kidney failure (defined as the initiation of KRT) and (2) death.
The following variables were available for analysis: age, sex, ethnicity (white, black, South
Asian, or other), smoking status (current smoker, previous smoker, never smoked), co-mor-
bidities (diabetes mellitus [DM], ischaemic heart disease [IHD], cerebrovascular disease,
peripheral artery disease [PAD], chronic obstructive pulmonary disease [COPD], and malig-
nancy), cause of CKD (vascular, diabetes, glomerular, tubulointerstitial, cystic or congenital,
or other or unknown), mean arterial pressure (MAP), estimated glomerular filtration rate
(eGFR, calculated using the 4-variable Modification of Diet in Renal Disease formula), and
urine albumin-to-creatinine ratio (ACR).
Table 1. Number of participants included and characteristics of each cohort study. ACR in mg/mmol; eGFR in ml/min/1.73 m2.
Study Number
included
Setting Inclusion criteria Exclusion criteria Years of
recruitment
End of
follow-up
Median (IQR)
follow-up
(months)
RIISC 878 Secondary
care
(1) eGFR < 30 or (2) eGFR 30–59
with (a) eGFR decline� or (b) urine
ACR > 70
(1) Previous dialysis or kidney
transplant
(2) Immunosuppression for
immune-mediated kidney disease
2010 to 2015 End of
2018
74 (64 to 83)
SKS 861 Secondary
care
eGFR >10 to <60 Previous dialysis or kidney
transplant
2002 to 2010 End of
2017
139 (110 to 161)
RRID 1,739 Primary
care
eGFR 30–59 (1) Expected survival <1 year
(2) Previous solid organ transplant
2008 to 2010 End of
2015
61 (60 to 63)
eGFR units are ml/min/1.73 m2; ACR units are mg/mmol.
�eGFR decline defined as � 5 ml/min/1.73 m2 per year, or� 10 ml/min/1.73 m2 over 5 years.
ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; IQR, interquartile range; RIISC, Renal Impairment in Secondary Care; RRID, Renal Risk
in Derby; SKS, Salford Kidney Study.
https://doi.org/10.1371/journal.pmed.1003050.t001
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No formal sample size calculations were carried out for these analyses, which were per-
formed using the available specimen collections and datasets.
Statistical analysis
Missing data were assumed to be missing at random, and multiple imputation using chained
equations was performed. Results of complete case analyses were similar and are provided in
S1 and S2 Tables.
Continuous variables all had skewed distributions as assessed by histograms. The relation-
ships of MG or LC-MG status with other categorical baseline variables were assessed using
Fisher’s exact test, and relationships with continuous variables were assessed using the Wil-
coxon rank-sum test.
The prognostic significance of an MG or LC-MG for risk of kidney failure was estimated by
competing-risks regression (the Fine and Gray method [14]) to account for the competing risk
of death, and expressed as a subhazard ratio (SHR) with 95% confidence interval (CI). The
associations with risk of death were estimated using Cox proportional hazards models and
expressed as hazard ratios (HRs) with 95% CI. Log–log plots were assessed for each variable to
ensure that the proportional hazards assumption was not violated. Following an initial statisti-
cal review of our study, robust estimates of variance were used in all regression models, which
are less sensitive to the presence of outliers. In analyses that included amalgamated data from
all 3 cohorts, clustering was accounted for by the use of stratified models, in which the baseline
hazard is allowed to vary by cohort. However, the estimated coefficient for a particular predic-
tor variable is equal across cohorts.
All variables included in multivariable models were pre-specified, based on established
prognostic factors for kidney failure and death in patients with CKD. Dummy variables were
created for categorical variables with more than 2 categories, and fractional polynomials
were used to explore the presence of non-linear relationships between continuous predictors
and each outcome. Where fractional polynomials provided a better model fit, plots of risk
against the variable on its original scale are presented to aid appreciation of the non-linear
relationship.
Results
Any non-malignant MG
In total, 878 participants from the RIISC cohort were included, and 102 (11.6%) of these had
an MG. Types of MG were as follows: 63 (61.8%) were IgG, 8 (7.8%) were IgM, 5 (4.9%) were
IgA, 1 (1.0%) was biclonal (IgG and IgM), and 25 (24.5%) were LC-MG. Study population
characteristics and the relationship between MG status and other baseline variables are shown
in Table 2. Compared to those without an MG, those with an MG were on average older
(P< 0.001), and a higher proportion had a history of malignancy (P = 0.037). For all other
baseline variables, there were no statistically significant differences between those with and
those without an MG.
Kidney failure
In total, 327 (37.2%) participants progressed to kidney failure, with rates per 100 person-years
of 10.5 and 9.3 for those with and without MG, respectively. The univariable associations
between baseline variables and the risk of kidney failure are shown in Table 2. Age, eGFR, and
urine ACR had non-linear relationships with the risk of kidney failure (Fig 1). The presence of
Non-malignant monoclonal gammopathy in chronic kidney disease
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an MG did not have a significant association with the risk of kidney failure (SHR 0.97 [95% CI
0.68 to 1.38], P = 0.85; Fig 2).
The multivariable model for kidney failure is shown in Table 2. After adjustment for age, sex,
ethnicity, cause of CKD, MAP, eGFR, and urine ACR, the presence of an MG was not signifi-
cantly associated with risk of kidney failure (SHR 1.16 [95% CI 0.80 to 1.69], P = 0.43). Younger
age, female sex, black ethnicity, a cystic or congenital cause of CKD, a lower eGFR, and a higher
urine ACR were all associated with a higher risk of kidney failure. In this multivariable model,
age, eGFR, and urine ACR had non-linear associations with risk of kidney failure (Fig 3).
Death
In total, 202 (23.0%) participants died. The death rates per 100 person-years were 10.8 and 5.3
for those with and without MG, respectively. The presence of an MG was associated with a
Table 2. Baseline characteristics of 878 participants of the RIISC study with CKD by MG status.
Variable All With MG Without MG Completeness of data (%)
N (%) 878 102 (11.6) 776 (88.4) 100
Age (years) 64.6 (51.7 to 76.0) 73.8 (59.8 to 81.4) 63.7 (50.2 to 75.5) 100
Sex male 542 (61.7) 66 (64.7) 476 (61.3) 100
Ethnicity 100
White 598 (68.1) 68 (66.7) 530 (68.3)
South Asian 188 (21.4) 24 (23.5) 164 (21.1)
Black 84 (9.6) 9 (8.9) 75 (9.7)
Other 8 (0.9) 1 (1.0) 7 (0.9)
Co-morbidities 100
DM 341 (38.8) 48 (47.1) 293 (37.8)
IHD 208 (23.7) 30 (29.4) 178 (22.9)
Cerebrovascular disease 102 (11.6) 15 (14.7) 87 (11.2)
PAD 93 (10.6) 14 (13.7) 79 (10.2)
COPD 89 (10.1) 8 (7.8) 81 (10.4)
Malignancy 128 (14.6) 22 (21.6) 106 (13.7)
Smoking status 98.2
Never 416 (48.3) 47 (47.0) 369 (48.4)
Previous 333 (38.6) 40 (40.0) 293 (38.5)
Current 113 (13.1) 13 (13.0) 100 (13.1)
Cause of CKD 91.2
Vascular 230 (28.7) 34 (36.2) 196 (27.7)
Diabetes 125 (15.6) 20 (21.3) 105 (14.9)
Glomerular 109 (13.6) 7 (7.4) 102 (14.4)
Tubulointerstitial 89 (11.1) 6 (6.4) 83 (11.7)
Cystic or congenital 66 (8.2) 4 (4.3) 62 (8.8)
Other or unknown 182 (22.7) 23 (24.5) 159 (22.5)
MAP (mm Hg) 93 (85 to 102) 92 (83 to 103) 93 (86 to 102) 97.6
eGFR (ml/min/1.73 m2) 31 (23 to 42) 28 (22 to 42) 31 (23 to 42) 96.8
Urine ACR (mg/mmol) 33.4 (6.3 to 130.0) 32.7 (5.6 to 161.2) 33.4 (6.5 to 122.7) 94.0
Categorical variables are shown as frequency (percentage), and continuous variables as median (interquartile range).
ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular
filtration rate; IHD, ischaemic heart disease; MAP, mean arterial pressure; MG, monoclonal gammopathy; PAD, peripheral artery disease; RIISC, Renal Impairment in
Secondary Care.
https://doi.org/10.1371/journal.pmed.1003050.t002
Non-malignant monoclonal gammopathy in chronic kidney disease
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003050 February 28, 2020 6 / 17
higher risk of death in the univariable model (HR 2.13 [95% CI 1.49 to 3.02], P< 0.001), as
shown in Table 2 and Fig 4. However, in the multivariable model, adjusting for age, sex, eth-
nicity, co-morbidities, smoking status, eGFR, and urine ACR, the presence of an MG no lon-
ger had a statistically significant association with death (HR 1.37 [95% CI 0.93 to 2.00],
Table 3. Association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional
hazards regression, expressed as HR with 95% CI) in 878 participants from the RIISC study with CKD.
Variable Kidney failure Death
Univariable Multivariable Univariable Multivariable
SHR 95% CI P SHR 95% CI P HR 95% CI P HR 95% CI P
With MG 0.97 0.68 to 1.38 0.85 1.16 0.80 to 1.69 0.43 2.13 1.49 to 3.02 <0.001 1.37 0.93 to 2.00 0.11
Age 1.00a 1.00 to 1.00 <0.001 1.00a 0.99 to 1.00 <0.001 3.36 2.73 to 4.12 <0.001 2.83 2.21 to 3.64 <0.001
Male sex 0.99 0.79 to 1.23 0.92 0.55 0.44 to 0.69 <0.001 1.27 0.95 to 1.69 0.11 0.88 0.62 to 1.24 0.46
Ethnicity
White Ref Ref Ref Ref
South Asian 2.02 1.58 to 2.57 <0.001 1.29 0.98 to 1.69 0.07 0.51 0.33 to 0.78 0.002 0.91 0.58 to 1.42 0.67
Black 1.98 1.42 to 2.76 <0.001 1.77 1.32 to 2.38 <0.001 0.80 0.48 to 1.33 0.39 1.13 0.67 to 1.90 0.65
Other 2.64 1.07 to 6.55 0.036 1.82 0.91 to 3.62 0.09 0.56 0.08 to 3.86 0.56 0.66 0.16 to 2.72 0.57
Co-morbidities
DM 0.92 0.73 to 1.15 0.46 1.64 1.25 to 2.16 <0.001 1.27 0.94 to 1.72 0.12
IHD 0.85 0.65 to 1.11 0.22 2.44 1.83 to 3.24 <0.001 1.44 1.05 to 1.96 0.022
Cerebrovascular disease 0.77 0.53 to 1.13 0.18 1.97 1.38 to 2.81 <0.001 1.27 0.87 to 1.85 0.21
PAD 0.86 0.59 to 1.27 0.45 2.21 1.57 to 3.11 <0.001 1.27 0.85 to 1.91 0.24
COPD 0.45 0.28 to 0.72 0.001 1.46 0.99 to 2.16 0.06 1.14 0.74 to 1.77 0.55
Malignancy 0.51 0.35 to 0.76 0.001 2.16 1.56 to 2.99 <0.001 1.56 1.10 to 2.22 0.013
Smoking status
Never Ref Ref Ref
Previous 0.69 0.54 to 0.88 0.003 1.73 1.28 to 2.34 <0.001 1.06 0.76 to 1.49 0.74
Current 1.07 0.78 to 1.47 0.71 1.14 0.71 to 1.84 0.58 1.25 0.70 to 2.24 0.45
Cause of CKD
Vascular Ref Ref Ref
Diabetes 1.92 1.33 to 2.78 0.001 1.05 0.69 to 1.60 0.81 0.81 0.52 to 1.26 0.35
Glomerular 1.19 0.81 to 1.76 0.38 1.00 0.66 to 1.51 1.00 0.22 0.11 to 0.41 <0.001
Tubulointerstitial 0.89 0.57 to 1.38 0.59 0.63 0.37 to 1.06 0.08 0.31 0.16 to 0.59 <0.001
Cystic or congenital 2.85 2.01 to 4.04 <0.001 3.99 2.74 to 5.83 <0.001 0.26 0.10 to 0.63 0.003
Other or unknown 1.24 0.89 to 1.73 0.21 1.21 0.85 to 1.73 0.28 0.82 0.57 to 1.17 0.27
MAP 1.39 1.25 to 1.54 <0.001 0.93 0.83 to 1.06 0.28 0.79 0.68 to 0.93 0.005
eGFR
1.18b 1.14 to 1.22 <0.001 0.94b 0.93 to 0.96 <0.001 0.45 0.36 to 0.56 <0.001 0.67 0.53 to 0.86 0.002
1.06c 1.05 to 1.07 <0.001 3.26d 2.73 to 3.91 <0.001
Urine ACR
1.48e 1.37 to 1.59 <0.001 3.30f 2.61 to 4.17 <0.001 0.78g 0.63 to 0.96 0.018 1.24 1.07 to 1.45 0.005
1.00a 1.00 to 1.00 <0.001 1.01a 1.00 to 1.01 <0.001
Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) x3;
(b) x−2; (c) x-2ln(x); (d) x−1; (e) ln(x); (f) x0.5; (g) x. Two rows for a continuous variable indicate the SHR or HR for each power of the degree-2 fractional polynomial
transformation. Cells for variables not included in a particular multivariable model are shaded grey.
ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR,
estimated glomerular filtration rate; HR, hazard ratio; IHD, ischaemic heart disease; MAP, mean arterial pressure; MG, monoclonal gammopathy; PAD, peripheral
artery disease; RIISC, Renal Impairment in Secondary Care; SHR, subhazard ratio.
https://doi.org/10.1371/journal.pmed.1003050.t003
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P = 0.11; Table 2). Older age, a history of IHD or malignancy, lower eGFR, and higher urine
ACR were associated with a higher risk of death.
Non-malignant LC-MG
In total, 3,478 participants from the 3 cohorts were included, and 55 (1.6%) of these had an
LC-MG. Table 3 shows the study population characteristics and the relationship between
Fig 1. Non-linear univariable associations with risk of kidney failure in 878 participants of the Renal Impairment in Secondary Care study with chronic kidney
disease for age (relative to 60 years), estimated glomerular filtration rate (eGFR, relative to 30 ml/min/1.73 m2), and urine albumin-to-creatinine ratio (ACR,
relative to 30 mg/mmol).
https://doi.org/10.1371/journal.pmed.1003050.g001
Fig 2. Cumulative incidence function for kidney failure in 878 participants of the Renal Impairment in Secondary Care
study with chronic kidney disease, by presence or absence of monoclonal gammopathy (MG). MG present (black line);
MG absent (grey line). Dashed lines represent 95% CIs.
https://doi.org/10.1371/journal.pmed.1003050.g002
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LC-MG status and other baseline variables. Compared to those without an LC-MG, those with
an LC-MG were on average older (P< 0.001), a higher proportion were male (P = 0.006) and
of black ethnicity (P = 0.004), and a lower proportion had a history of IHD (P = 0.001) or PAD
(P = 0.004). There were no statistically significant differences between those with and those
without LC-MG with respect to all other baseline variables.
Fig 3. Non-linear associations with risk of kidney failure in 878 participants of the Renal Impairment in Secondary Care study with chronic kidney disease (CKD)
in a multivariable model containing monoclonal gammopathy status, age, sex, ethnicity, cause of CKD, mean arterial pressure, estimated glomerular filtration rate
(eGFR), and urine albumin-to-creatinine ratio (ACR), for age (relative to 60 years), eGFR (relative to 30 ml/min/1.73 m2), and urine ACR (relative to 30 mg/mmol).
https://doi.org/10.1371/journal.pmed.1003050.g003
Fig 4. Kaplan–Meier survival curves for 878 participants of the Renal Impairment in Secondary Care study with chronic
kidney disease by the presence or absence of monoclonal gammopathy (MG). MG present (black line); MG absent (grey
line).
https://doi.org/10.1371/journal.pmed.1003050.g004
Non-malignant monoclonal gammopathy in chronic kidney disease
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003050 February 28, 2020 9 / 17
Kidney failure
In total, 564 (16.2%) patients progressed to kidney failure, with rates per 100 person-years of
4.9 and 3.2 for those with and without an LC-MG, respectively. The univariable associations
between baseline variables and the risk of kidney failure are shown in Table 5. Age, eGFR, and
urine ACR had non-linear associations with risk of kidney failure in the univariable analyses
(Fig 5). The presence of an LC-MG did not have a significant association with the risk of kid-
ney failure (SHR 1.07 [95% CI 0.58 to 1.96], P = 0.82; Fig 6).
The multivariable model for kidney failure is shown in Table 5. After adjusting for age, sex,
ethnicity, MAP, eGFR, and urine ACR, the presence of an LC-MG did not have a statistically
significant association with risk of kidney failure (SHR 1.42 [95% CI 0.78 to 2.57], P = 0.26). In
this multivariable model, a younger age, black ethnicity, a lower eGFR, and a higher urine
ACR were associated with a higher risk of kidney failure, and the non-linear associations with
age, eGFR, and urine ACR are shown in Fig 7.
Death
In total, 803 (23.1%) participants died. Death rates were 9.3 and 4.5 per 100 person-years for
those with and without an LC-MG, respectively. The univariable associations between baseline
factors and death are shown in Table 5. LC-MG was associated with a higher risk of death (HR
2.51 [95% CI 1.59 to 3.96], P< 0.001), and Fig 8 shows Kaplan–Meier survival curves by
LC-MG status. The univariable analyses showed that MAP, eGFR, and urine ACR had non-lin-
ear associations with risk of death (Fig 9). In the multivariable model (Table 5), after adjustment
Table 4. Baseline characteristics for 3,478 participants with CKD from 3 cohort studies, by LC-MG status.
Variable All With LC-MG Without LC-MG Completeness of data (%)
N (%) 3,478 55 (1.6) 3,423 (98.4)
Age (years) 71.0 (61.2 to 78.0) 77.8 (71.0 to 82.0) 71.0 (61.1 to 78.0) 100
Sex (male) 1,760 (50.6) 38 (69.1) 1,722 (50.3) 100
Ethnicity 100
White 3,126 (89.9) 44 (80.0) 3,082 (90.0)
South Asian 237 (6.8) 5 (9.1) 232 (6.8)
Black 96 (2.8) 6 (10.9) 90 (2.6)
Other 19 (0.6) 0 (0.0) 19 (0.6)
Co-morbidities 100
DM 914 (26.3) 16 (29.1) 898 (26.2)
IHD 1,347 (38.7) 10 (18.2) 1,337 (39.1)
Cerebrovascular disease 395 (11.4) 3 (5.5) 392 (11.5)
PAD 879 (25.3) 5 (9.1) 874 (25.5)
Smoking status 99.5
Never 1,486 (43.0) 26 (47.3) 1,460 (42.9)
Previous 1,667 (48.2) 28 (50.9) 1,639 (48.1)
Current 307 (8.9) 1 (1.8) 306 (9.0)
MAP (mm Hg) 93 (86 to 102) 92 (85 to 99) 93 (86 to 102) 99.3
eGFR (ml/min/1.73 m2) 42.3 (26.2 to 54.4) 40.4 (24.3 to 54.2) 42.3 (26.3 to 54.4) 99.2
Urine ACR (mg/mmol) 3.4 (0.3 to 27.3) 4.7 (0.4 to 76.6) 3.4 (0.2 to 26.7) 95.5
Categorical variables are shown as frequency (percentage), and continuous variables as median (interquartile range).
ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease;
LC-MG, light chain monoclonal gammopathy; MAP, mean arterial pressure; PAD, peripheral artery disease.
https://doi.org/10.1371/journal.pmed.1003050.t004
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for age, sex, ethnicity, co-morbidities, smoking status, eGFR, and urine ACR, the presence of an
LC-MG did not have a statistically significant association with death (HR 1.49 [95% CI 0.93 to
2.39], P = 0.10). In this multivariable model, older age; male sex; a history of DM, IHD, or cere-
brovascular disease; being a previous or current smoker, a lower eGFR, and a higher urine ACR
(non-linear association; Fig 10) were associated with a higher risk of death.
Discussion
We evaluated the prognostic significance of non-malignant MG in patients with CKD. We
found the prevalence of non-malignant MG to be higher in our CKD population compared to
Table 5. Association between baseline variables and risk of kidney failure (competing-risks regression, expressed as SHR with 95% CI) and death (Cox proportional
hazards regression, expressed as HR with 95% CI) in 3,478 participants with CKD from 3 cohort studies.
Variable Kidney failure Death
Univariable Multivariable Univariable Multivariable
SHR 95% CI P SHR 95% CI P HR 95% CI P HR 95% CI P
With LC-MG 1.07 0.58 to 1.96 0.82 1.42 0.78 to 2.57 0.26 2.51 1.59 to 3.96 <0.001 1.49 0.93 to 2.39 0.10
Age
1.01a 1.00 to 1.02 0.20 1.00a 1.00 to 1.00 <0.001 2.88 2.60 to 3.19 <0.001 2.76 2.48 to 3.08 <0.001
1.00b 0.99 to 1.00 0.050
Male sex 0.95 0.81 to 1.12 0.53 1.14 0.96 to 1.37 0.13 1.59 1.37 to 1.84 <0.001 1.27 1.09 to 1.49 0.002
Ethnicity
White Ref Ref Ref Ref
South Asian 1.94 1.56 to 2.41 <0.001 1.15 0.89 to 1.48 0.30 0.67 0.47 to 0.94 0.022 1.11 0.79 to 1.56 0.56
Black 1.84 1.35 to 2.49 <0.001 1.71 1.29 to 2.27 <0.001 0.77 0.48 to 1.25 0.30 1.10 0.70 to 1.73 0.69
Other 2.80 1.34 to 5.86 0.006 1.42 0.55 to 3.62 0.47 0.48 0.12 to 1.94 0.30 0.79 0.29 to 2.14 0.64
Co-morbidities
DM 0.92 0.77 to 1.09 0.31 1.71 1.48 to 1.97 <0.001 1.42 1.22 to 1.65 <0.001
IHD 1.03 0.85 to 1.24 0.78 1.64 1.35 to 1.99 <0.001 1.31 1.10 to 1.56 0.002
Cerebrovascular disease 0.84 0.64 to 1.10 0.20 1.97 1.65 to 2.36 <0.001 1.39 1.15 to 1.69 0.001
PAD 1.10 0.88 to 1.36 0.41 0.93 0.70 to 1.22 0.58 0.93 0.76 to 1.14 0.49
Smoking status
Never Ref Ref Ref
Previous 0.72 0.60 to 0.86 <0.001 1.71 1.47 to 2.00 <0.001 1.26 1.07 to 1.48 0.005
Current 1.14 0.91 to 1.44 0.26 1.34 1.04 to 1.74 0.026 1.56 1.16 to 2.09 0.003
MAP
1.33 1.23 to 1.44 <0.001 1.07 0.97 to 1.18 0.16 0.00c 0.00 to 0.00 <0.001
71.39d 6.10 to 835.26 0.001
eGFR
1.17e 1.15 to 1.20 <0.001 0.96e 0.95 to 0.97 <0.001 0.00f 0.00 to 0.01 <0.001 0.65 0.58 to 0.74 <0.001
1.06g 1.05 to 1.06 <0.001 2.4h 2.10 to 2.80 <0.001
Urine ACR
10.97i 7.20 to 16.70 <0.001 3.58i 2.62 to 4.90 <0.001 1.68i 1.18 to 2.40 0.005 1.15c 1.09 to 1.22 <0.001
0.80f 0.68 to 0.95 0.008 0.40j 0.29 to 0.55 <0.001 1.01d 1.00 to 1.01 <0.001
Continuous variables are linear per 1 standard deviation unless otherwise indicated. Transformed continuous variables are indicated by the following footnotes: (a) x3;
(b) x3ln(x); (c) ln(x); (d) [ln(x)]2; (e) x−2; (f) x2; (g) x−2ln(x); (h) x−1; (i) x0.5; (j) x0.5ln(x). Two rows for a continuous variable indicate the SHR or HR for each power of
the degree-2 fractional polynomial transformation. Cells for variables not included in a particular multivariable model are shaded grey.
ACR, albumin-to-creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HR, hazard
ratio; IHD, ischaemic heart disease; LC-MG, light chain monoclonal gammopathy; MAP, mean arterial pressure; PAD, peripheral artery disease; SHR, subhazard ratio.
https://doi.org/10.1371/journal.pmed.1003050.t005
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reported estimates of prevalence for the general population [1]. However, the presence of an
MG was not associated with a higher risk of kidney failure or death after accounting for estab-
lished prognostic factors in CKD.
To the best of our knowledge, only 1 other study, by Haynes et al. [7], has assessed the rela-
tionship between MG and clinical outcomes in patients with CKD. Compared to our study,
that by Haynes et al. had far fewer participants (382), such that only 35 patients had MGUS.
Therefore, there is likely to be less bias in our estimates of the risk of kidney failure or death
associated with an MG in CKD.
Fig 5. Non-linear univariable associations with risk of kidney failure in 3,478 participants with chronic kidney disease from 3 cohort studies for age (relative to 70
years), estimated glomerular filtration rate (eGFR, relative to 40 ml/min/1.73 m2), and urine albumin-to-creatinine ratio (ACR, relative to 3 mg/mmol).
https://doi.org/10.1371/journal.pmed.1003050.g005
Fig 6. Cumulative incidence function for kidney failure in 3,478 participants with chronic kidney disease from 3 cohort
studies, by the presence or absence of light chain monoclonal gammopathy (LC-MG). LC-MG present (black line);
LC-MG absent (grey line). Dashed lines represent 95% CIs.
https://doi.org/10.1371/journal.pmed.1003050.g006
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The results of our study and the study by Haynes et al. suggest that the shorter survival asso-
ciated with MGUS in the general population is not seen in patients with CKD. It is possible
that neither study was large enough to detect a small increase in the risk of death. However, it
may be that the already significantly increased rate of death in individuals with CKD compared
to individuals without CKD renders any risk associated with an MG, which is primarily due to
malignant transformation over time, negligible.
Fig 7. Non-linear associations with risk of kidney failure in 3,478 participants with chronic kidney disease from 3 cohort studies in a multivariable model
containing light chain monoclonal gammopathy status, age, sex, ethnicity, mean arterial pressure, estimated glomerular filtration rate (eGFR), and urine albumin-
to-creatinine ratio (ACR), for age (relative to 70 years), eGFR (relative to 40 ml/min/1.73 m2), and urine ACR (relative to 3 mg/mmol).
https://doi.org/10.1371/journal.pmed.1003050.g007
Fig 8. Kaplan–Meier survival curves for 3,478 participants with chronic kidney disease from 3 cohort studies by the
presence or absence of light chain monoclonal gammopathy (LC-MG). LC-MG present (black line); LC-MG absent (grey
line).
https://doi.org/10.1371/journal.pmed.1003050.g008
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Our finding of a higher prevalence of MG in CKD is also consistent with the study by
Haynes et al. and appears attributable to an increased prevalence of both intact immunoglobu-
lin MG and LC-MG. The prevalence of total MGUS in the Olmsted County cohort in individ-
uals aged 70–79 was 5.9%, and the prevalence of light chain MGUS was 1.1% [15]; in our
study, the crude prevalence was 11.6% for total MGUS (median age 73.8 years) and 1.6% for
light chain MGUS (median age 77.8 years).
Fig 9. Non-linear univariable associations with risk of death in 3,478 participants with chronic kidney disease from 3 cohort studies for mean arterial pressure
(relative to 90 mm Hg), estimated glomerular filtration rate (eGFR, relative to 40 ml/min/1.73 m2), and urine albumin-to-creatinine ratio (ACR, relative to 3 mg/
mmol).
https://doi.org/10.1371/journal.pmed.1003050.g009
Fig 10. Non-linear association of urine albumin-to-creatinine ratio (ACR, relative to 3 mg/mmol) with risk of death in
3,478 participants with chronic kidney disease from 3 cohort studies in a multivariable model containing light chain
monoclonal gammopathy status, age, sex, ethnicity, co-morbidities, smoking status, estimated glomerular filtration
rate, and urine ACR.
https://doi.org/10.1371/journal.pmed.1003050.g010
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A significant strength of this study was the inclusion of participants from multiple cohorts
from both primary and secondary care and that it is the largest cohort to date of patients with
MGUS and CKD. A significant limitation was the absence of SPEP and immunofixation data
from the SKS and RRID cohorts. We could, therefore, detect only LC-MG in these cohorts,
and many patients with an intact Ig MG would not have been identified. However, in the
RIISC study, where SPEP and immunofixation were performed on serum from all partici-
pants, the presence of any non-malignant MG was not associated with a higher risk of kidney
failure or death.
Further, we did not assess the association of MGUS in this CKD population with other clin-
ically important outcomes that are associated with MGUS in those without CKD, such as car-
diovascular events, infections, or the evolution of an MG to multiple myeloma or other
paraprotein-related diseases. We also did not examine CKD progression (via change in eGFR)
with time, which would be a more sensitive marker for MG-associated kidney damage than
the outcome of kidney failure.
Further research is required concerning the prognostic implications of non-malignant MG
in patients with CKD. However, based on the results of our study, these patients and their
healthcare providers may be reassured that the presence of an MG does not significantly
increase the risk of kidney failure or death that is associated with CKD.
In conclusion, the prevalence of non-malignant MG appears to be higher in patients with
CKD than in the general population. However, its presence is not independently associated
with a significantly higher risk of kidney failure or death.
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